Vitamin E and Omega-3 Fatty Acids in NASH and Fatty Liver Disease
Introduction to Treatment
- The American Association for the Study of Liver Diseases recommends Vitamin E (α-tocopherol) at 800 IU/day as first-line pharmacotherapy for non-diabetic adults with biopsy-proven NASH, while omega-3 fatty acids should not be used specifically for NAFLD/NASH treatment but may be considered for managing hypertriglyceridemia in these patients 1, 2
Vitamin E in NAFLD/NASH
- Vitamin E (α-tocopherol) at 800 IU/day significantly improves liver histology in non-diabetic adults with biopsy-proven NASH, with a strength of evidence supported by the PIVENS trial, which achieved the primary endpoint in 42% of participants versus 19% with placebo (p<0.001, NNT=4.4) 1, 3, 4, 5
- Vitamin E demonstrates improvements in steatosis, inflammation, ballooning degeneration, and resolution of steatohepatitis in non-diabetic adults with biopsy-proven NASH 6, 7, 8, 9
- Vitamin E has no demonstrated effect on hepatic fibrosis in non-diabetic adults with biopsy-proven NASH 7, 8
Omega-3 Fatty Acids in NAFLD/NASH
- Current guidelines state it is premature to recommend omega-3 fatty acids specifically for NAFLD/NASH treatment, although they may be beneficial for managing hypertriglyceridemia in these patients 1, 2
- Omega-3 fatty acids can lower triglycerides, which may indirectly benefit NAFLD patients, and are approved and recommended as first-line agents for hypertriglyceridemia in NAFLD patients 1, 2
Treatment Algorithm for NAFLD/NASH
- For non-diabetic adults with biopsy-proven NASH, first-line pharmacotherapy is Vitamin E (α-tocopherol) 800 IU/day, and omega-3 fatty acids may be considered for managing hypertriglyceridemia 1, 3
- For NAFLD patients with hypertriglyceridemia, omega-3 fatty acids are recommended as first-line treatment for the lipid abnormality, which may provide additional benefit for hepatic steatosis 1, 2